NPI-0052
Published: Nov 4, 2009 11:33 am
| Brand Name: | |
| Generic Name: | |
| Code Name: | NPI-0052 |
| Company: | Nereus Pharmaceuticals |
| FDA Clinical Phase: | 1 |
Description:
NPI-0052 is a novel proteasome inhibitor that suppresses tumor growth by inhibiting the enzymes that break down important proteins in cancerous cells. NPI-0052 may be used as an alternative treatment to Velcade (bortezomib), the first approved proteasome inhibitor, because it has shown significant activity against multiple myeloma that was previously resistant to Velcade. NPI-0052 is often administered orally or intravenously as either a single agent or in combination with other anti-cancer agents.
Clinical Trials:
Currently, there are currently several open clinical studies involving NPI-0052.
Official Web site for NPI-0052: http://www.nereuspharm.com/NPI-0052.shtml
Updated November 4, 2009
Related Articles:
- ASH 2008 – Carfilzomib, A Novel Drug Related To Velcade, Reduces Peripheral Neuropathy
- Carfilzomib Is Highly Active In Relapsed Myeloma Patients
- Vitamin C Inhibits Anti-Myeloma Activity Of Velcade
- Research Shows Velcade’s Possible Mechanism of Action
- Perifosine Advances To Phase 3 Multiple Myeloma Clinical Trial
Leave a comment